JP2009522578A5 - - Google Patents

Download PDF

Info

Publication number
JP2009522578A5
JP2009522578A5 JP2008549563A JP2008549563A JP2009522578A5 JP 2009522578 A5 JP2009522578 A5 JP 2009522578A5 JP 2008549563 A JP2008549563 A JP 2008549563A JP 2008549563 A JP2008549563 A JP 2008549563A JP 2009522578 A5 JP2009522578 A5 JP 2009522578A5
Authority
JP
Japan
Prior art keywords
patient
marker
determining
markers
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008549563A
Other languages
English (en)
Japanese (ja)
Other versions
JP5221381B2 (ja
JP2009522578A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/000216 external-priority patent/WO2007081768A2/en
Publication of JP2009522578A publication Critical patent/JP2009522578A/ja
Publication of JP2009522578A5 publication Critical patent/JP2009522578A5/ja
Application granted granted Critical
Publication of JP5221381B2 publication Critical patent/JP5221381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008549563A 2006-01-04 2007-01-04 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用 Active JP5221381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75613106P 2006-01-04 2006-01-04
US60/756,131 2006-01-04
PCT/US2007/000216 WO2007081768A2 (en) 2006-01-04 2007-01-04 Use of he4 and other biochemical markers for assessment of ovarian cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012226640A Division JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Publications (3)

Publication Number Publication Date
JP2009522578A JP2009522578A (ja) 2009-06-11
JP2009522578A5 true JP2009522578A5 (https=) 2010-02-25
JP5221381B2 JP5221381B2 (ja) 2013-06-26

Family

ID=38256906

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008549562A Active JP5164855B2 (ja) 2006-01-04 2007-01-04 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
JP2008549563A Active JP5221381B2 (ja) 2006-01-04 2007-01-04 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用
JP2012226640A Active JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008549562A Active JP5164855B2 (ja) 2006-01-04 2007-01-04 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012226640A Active JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Country Status (7)

Country Link
US (8) US20070286865A1 (https=)
EP (6) EP1969136A4 (https=)
JP (3) JP5164855B2 (https=)
CN (3) CN106124765A (https=)
ES (2) ES2650244T3 (https=)
PL (1) PL2982761T3 (https=)
WO (2) WO2007081768A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5731400A (en) * 1999-06-09 2000-12-28 Moltech Corporation Methods of preparing electrochemical cells
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP1877795A4 (en) * 2005-05-02 2010-04-28 Brigham & Womens Hospital DIAGNOSTIC PROFILE MANUFACTURE OF SERUM ANTIBODIES
JP5164855B2 (ja) * 2006-01-04 2013-03-21 フジレビオ アメリカ、インク． 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
MX2008009592A (es) * 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
US8329399B2 (en) 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
BRPI0808655A2 (en) * 2007-03-09 2018-10-23 Tripath Imaging, Inc. he4 monoclonal antibodies and methods for their use.
US8455189B2 (en) * 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
CN101377502A (zh) * 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 肿瘤相关抗原72-4化学发光免疫分析测定试剂盒及其制备方法
WO2009099561A2 (en) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Urinary ca125 peptides as biomarkers of ovarian cancer
WO2009145815A2 (en) * 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
JP6097688B2 (ja) * 2010-08-26 2017-03-15 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 抗ｈｅ４抗体を検出するための方法、ならびにｈｅ４発現細胞と関連する状態の診断および／または予後判定のための方法
RU2650778C2 (ru) 2011-02-17 2018-04-17 Фуджиребио Диагностикс, Инк Композиции и способы применения для определения не4а
KR20140024860A (ko) * 2011-02-24 2014-03-03 버밀리언, 인코포레이티드 난소암에 대한 바이오마커 패널，진단 방법 및 시험 키트
CN102735840B (zh) * 2011-04-13 2014-06-04 中国医学科学院肿瘤研究所 用于诊断或筛查卵巢癌的试剂
WO2012170513A2 (en) * 2011-06-06 2012-12-13 Women & Infants' Hospital Of Rhode Island He4 based therapy for malignant disease
DE102012205164B4 (de) 2012-03-29 2021-09-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Projektionsdisplay und Verfahren zur Projektion virtueller Bilder
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
CN102890083B (zh) * 2012-09-28 2016-08-10 辽宁科骏生物有限公司 化学发光底物溶液和含其的试剂盒及应用其的检测方法
CN104655858B (zh) * 2015-03-12 2016-02-10 德迈基生物技术（北京）有限公司 定量检测人附睾分泌蛋白-4的荧光免疫层析试剂盒及其制备方法
EP3273974A4 (en) 2015-03-26 2018-11-07 Women and Infants Hospital of Rhode Island Inc. Therapy for malignant disease
RU2585959C1 (ru) * 2015-06-22 2016-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики асцитно-инфильтративной формы рака яичников и абдоминального туберкулёза
US10267802B2 (en) 2015-09-23 2019-04-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of prognosis and diagnosis of ovarian cancer
RU2624508C1 (ru) * 2016-06-29 2017-07-04 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования длительности ремиссии у больных раком вульвы
JP2019524706A (ja) * 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
CA3175499A1 (en) 2020-04-21 2021-10-28 University Of Rochester Inhibitors of human epididymus protein 4
CN111781364B (zh) * 2020-08-25 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和HE4联合用作早期卵巢癌生物标志物以及试剂盒
CA3202255A1 (en) 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
US20240385195A1 (en) * 2022-04-08 2024-11-21 Ajou University Industry-Academic Cooperation Foundation Peptide for detecting ca125 and use thereof
US20240353411A1 (en) * 2022-04-08 2024-10-24 Ajou University Industry-Academic Cooperation Foundation He4 detecting peptide and use thereof
CN120254284B (zh) * 2025-06-03 2025-08-22 杭州广科安德生物科技有限公司 一种用于预测子宫内膜癌复发或转移风险的生物标志物及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6998106B1 (en) * 1998-12-01 2006-02-14 Duke University Radioconjugation of internalizing antibodies
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
CA2369433A1 (en) 1999-02-26 2000-08-31 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
KR101107765B1 (ko) * 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
EP2315027A1 (en) * 2002-08-16 2011-04-27 Decision Biomarkers Incorporated Substrates for isolating, reacting and microscopically analyzing materials
WO2004072638A1 (en) * 2003-02-05 2004-08-26 Ciphergen Biosystems, Inc. Non-invasive assessment of intra-amniotic environment
WO2004101756A2 (en) * 2003-05-09 2004-11-25 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN1266475C (zh) * 2003-06-05 2006-07-26 马旭 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
WO2005098446A2 (en) * 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
WO2006089125A2 (en) * 2005-02-16 2006-08-24 Dana-Farber Cancer Institute Methods of detecting ovarian cancer
CN101243319B (zh) * 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
WO2007002535A2 (en) * 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
JP5164855B2 (ja) * 2006-01-04 2013-03-21 フジレビオ アメリカ、インク． 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用

Similar Documents

Publication Publication Date Title
JP2009522578A5 (https=)
Jin et al. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma
Jia et al. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis
Abel et al. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment
Choi et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation
WO2010065968A1 (en) Cancer detection markers
US11402381B2 (en) Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses
US10139412B2 (en) Semaphorin 3A as a diagnostic marker for urothelial cancer
CN102298053B (zh) 原发性肝细胞肝癌术后复发风险评估的组合抗体试剂盒
CN109425739A (zh) 一组蛋白作为肿瘤标志物在制备恶性肿瘤诊断试剂和试剂盒中的用途
US20180292410A1 (en) Methods of detecting a relapse of a lung adenocarcinoma based on marker human epididymis protein 4 (he4) and related uses
Provenzano et al. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple‐negative tumours
Chen et al. Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma
Tanaka et al. Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer
Hashmi et al. Clinicopathologic patterns of adult renal tumors in Pakistan
JP2011209101A (ja) ＣａｐＧをマーカーとする悪性腫瘍の予後予測検査方法
Innaro et al. Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell‐based cytology
CN118308490A (zh) 不明原发灶肿瘤组织溯源检测标志物的用途及检测系统
Alrashidy et al. Immunohistochemical differentiation between urothelial papillomas and papillary neoplasms of low malignant potential of the urinary bladder
Potempa-Jeziorowska Salivary biomarkers for monitoring the course of cancer development–real perspectives
Makkai-Popa et al. Corelation of lymphocytic infiltrates with the prognosis of recurrent colo-rectal cancer
Cho et al. CDX-2 protein and mRNA expression in canine intestinal adenocarcinoma
Wu et al. Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma Patients
CN116593702A (zh) 一种肺癌的生物标志物以及诊断系统
Maqbool et al. Assessment of Tumour Budding in Colorectal Adenocarcinomas